Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MEX:CRL's EV-to-OCF is ranked worse than 83.02% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.235
vs MEX:CRL: 27.92
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Charles River Laboratories International (MEX:CRL) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Charles River Laboratories International's PE Ratio (TTM) for today is calculated as:
Charles River Laboratories International's share price for today is MXN4720.00.
Charles River Laboratories International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-87.083.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Charles River Laboratories International EV-to-OCF Related Terms
Charles River Laboratories International EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International EV-to-OCF Chart
Charles River Laboratories International Annual Data
For the Diagnostics & Research subindustry, Charles River Laboratories International's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's EV-to-OCF falls into.
Charles River Laboratories International's current Enterprise Value is MXN276,882 Mil.
Charles River Laboratories International's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN10,455 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International (MEX:CRL) has a EV-to-OCF of 26.48 as of Aug. 16, 2026. This is 32% above median its historical median of 19.99. Over the past decade, Charles River Laboratories International's EV-to-OCF has ranged from 10.15 to 39.17. According to the industry distribution chart, Charles River Laboratories International ranks #176 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 83%.
Is Charles River Laboratories International's EV-to-OCF too high?
Charles River Laboratories International's current EV-to-OCF of 26.48 is 32% above median its 10-year median of 19.99. Over the past 10 years, this metric has ranged from a low of 10.15 to a high of 39.17. The Medical Diagnostics & Research industry median EV-to-OCF is 6.24. Charles River Laboratories International's value of 26.48 is 324.7% above this industry median. Based on the distribution chart, Charles River Laboratories International ranks #176 out of 212 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Charles River Laboratories International has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's EV-to-OCF compare to RVTY and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #176 out of 212 companies for EV-to-OCF. This places Charles River Laboratories International in the lower half of its industry. The industry median EV-to-OCF is 6.24. Charles River Laboratories International's value of 26.48 is 324.7% above this benchmark. Historically, Charles River Laboratories International's own EV-to-OCF has ranged from 10.15 to 39.17 over the past decade. While the company's 10-year median is 19.99 vs. the industry median of 6.24, Charles River Laboratories International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.24, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charles River Laboratories International's current EV-to-OCF of 26.48 is 324.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current EV-to-OCF is 26.48, which is 32% above median its own 10-year median of 19.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (MEX:CRL) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,782.12, compared to a current price of MXN4,720.00 — trading 69.7% above its estimated fair value. The current EV-to-OCF is 26.48, which is 32% above median its 10-year median of 19.99 and 324.7% above the Medical Diagnostics & Research industry median of 6.24. Charles River Laboratories International's overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Charles River Laboratories International (MEX:CRL), the current EV-to-OCF is 26.48 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (MEX:CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of MXN4,720.00 is trading 69.7% above its estimated GF Value™ of MXN2,782.12.
GuruFocus considers Charles River Laboratories International to be Significantly Overvalued.
Key valuation signals for MEX:CRL:
EV-to-OCF: 26.48 (32% above median its 10-year median of 19.99)
GF Value™: MXN2,782.12 vs. price of MXN4,720.00 (69.7% above fair value)
Industry Position: 324.7% above the Medical Diagnostics & Research median (#176 of 212)
No single metric tells the full story. See the MEX:CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
51GF Score
Get the complete analysis for MEX:CRL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:CRL has been successfully added to your 
